Understanding how RNA oxidation affects the onset and progression of ALS
Elucidating the role of RNA oxidation on amyotrophic lateral sclerosis onset and progression
This study is looking at how damaged RNA might play a role in the development of ALS, focusing on how it affects the health of motor neurons, and it's designed for people interested in understanding more about the disease and its progression.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11178244 on NIH RePORTER |
What this research studies
This research investigates the role of RNA oxidation in the development and progression of Amyotrophic Lateral Sclerosis (ALS). It aims to determine whether oxidative stress is a cause or consequence of the disease by examining how oxidized RNA affects motor neuron function. The study will utilize induced pluripotent stem cell (iPSC)-derived motor neurons to identify which RNA transcripts are oxidized in the early stages of ALS and how this impacts neuronal health. By exploring the interaction between oxidized RNAs and RNA Binding Proteins (RBPs), the research seeks to uncover new mechanisms that contribute to motor neuron degeneration.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with early-stage Amyotrophic Lateral Sclerosis.
Not a fit: Patients with advanced stages of ALS or those with other neurodegenerative diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies targeting RNA oxidation to slow or prevent the progression of ALS.
How similar studies have performed: While the role of oxidative stress in ALS has been studied, the specific focus on RNA oxidation and its mechanisms is relatively novel and untested.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Chaim, Isaac Alexander — University of California, San Diego
- Study coordinator: Chaim, Isaac Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.